Loading...
Verano Holdings Corp.
VRNO.NE•NEO
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.95
CA$0.15(18.75%)
Verano Holdings Corp. (VRNO.NE) Financial Performance & Income Statement Overview
Review Verano Holdings Corp.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-6.38%
↓ 6.38%
Operating Income Growth
-379.74%
↓ 379.74%
Net Income Growth
-191.32%
↓ 191.32%
Operating Cash Flow Growth
2.27%
↑ 2.27%
Operating Margin
-28.24%
↓ 28.24%
Gross Margin
49.65%
↑ 49.65%
Net Profit Margin
-40.20%
↓ 40.20%
ROE
-32.16%
↓ 32.16%
ROIC
-13.59%
↓ 13.59%
Verano Holdings Corp. (VRNO.NE) Income Statement & Financial Overview
Review Verano Holdings Corp.'s (VRNO.NE) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $218.21M | $216.68M | $222.34M | $220.32M |
| Cost of Revenue | $110.67M | $107.59M | $112.14M | $111.88M |
| Gross Profit | $107.53M | $109.10M | $110.20M | $108.43M |
| Gross Profit Ratio | $0.49 | $0.50 | $0.50 | $0.49 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $350825.00 |
| SG&A Expenses | $83.72M | $92.33M | $82.94M | $85.86M |
| Operating Expenses | $411.42M | $92.33M | $82.94M | $85.86M |
| Total Costs & Expenses | $522.09M | $199.91M | $195.08M | $197.75M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $12.64M | $12.77M | $14.24M | $15.11M |
| Depreciation & Amortization | $33.25M | $39.52M | $39.61M | $38.49M |
| EBITDA | -$272.36M | $55.20M | $62.62M | $60.88M |
| EBITDA Ratio | -$1.25 | $0.25 | $0.28 | $0.28 |
| Operating Income | -$303.88M | $16.77M | $27.26M | $22.57M |
| Operating Income Ratio | -$1.39 | $0.08 | $0.12 | $0.10 |
| Other Income/Expenses (Net) | -$14.36M | -$13.86M | -$18.50M | -$15.94M |
| Income Before Tax | -$318.25M | $2.91M | $8.76M | $6.63M |
| Income Before Tax Ratio | -$1.46 | $0.01 | $0.04 | $0.03 |
| Income Tax Expense | -$45.54M | $45.48M | $30.52M | $11.43M |
| Net Income | -$272.71M | -$42.57M | -$21.76M | -$4.80M |
| Net Income Ratio | -$1.25 | -$0.20 | -$0.10 | -$0.02 |
| EPS | -$0.76 | -$0.12 | -$0.06 | -$0.01 |
| Diluted EPS | -$0.76 | -$0.12 | -$0.06 | -$0.01 |
| Weighted Avg Shares Outstanding | $358.75M | $351.17M | $345.02M | $344.08M |
| Weighted Avg Shares Outstanding (Diluted) | $358.75M | $351.17M | $345.02M | $344.08M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan